Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
In8Bio, Inc. (INAB) is a clinical-stage biopharmaceutical leader developing gamma-delta T cell immunotherapies for cancer treatment. This page provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships driving innovation in cellular therapies.
Access real-time announcements about the company's DeltEx platform advancements, chemotherapy-resistant cell therapies, and progress across solid tumor and hematologic malignancy programs. Our curated news collection includes earnings reports, trial data publications, and collaborative research milestones.
Key updates cover FDA designations, preclinical study results, and technology licensing agreements. All content is verified for accuracy and relevance to support informed decision-making in the oncology investment space.
Bookmark this page for streamlined access to In8Bio's latest scientific achievements and corporate developments. Check regularly for authoritative updates on one of biotech's most promising cancer immunotherapy innovators.
IN8bio (Nasdaq: INAB) presented promising preliminary data of INB-200 for glioblastoma at the 2024 ASCO Annual Meeting. The Phase 1 study of INB-200 showed that 92% of patients surpassed the median progression-free survival (PFS) of 7 months achieved with the standard Stupp regimen, with a median follow-up of 11.7 months. Notably, one patient remained progression-free for nearly three years. The study involved 13 patients across three dosing regimens, revealing a favorable safety profile with no serious treatment-related adverse events. All patients completing the full treatment protocol exceeded the median PFS of 7 months, and radiologic evaluations indicated positive treatment effects. IN8bio is now progressing with a Phase 2 study to further evaluate the therapy.
IN8bio, a clinical-stage biopharmaceutical company listed on Nasdaq as INAB, announced its participation in the International Society for Cell & Gene Therapy (ISCT) 2024 from May 28 to June 1 in Vancouver, Canada. IN8bio will present multiple findings on their gamma-delta T cell therapies. Dr. Kate Rochlin, COO, emphasized the significance of these presentations in advancing their proprietary manufacturing platform. Highlights include the INB-400 DeltEx drug-resistant immunotherapy (DRI) multi-center clinical trial and analyses comparing healthy donor and patient-manufactured autologous DeltEx DRI products. These developments are poised to improve cancer patient outcomes by targeting and potentially eradicating cancer cells.
IN8bio announced the upcoming presentation of updated Phase 1 study results for INB-200 at the 2024 ASCO Annual Meeting. INB-200, an autologous Drug Resistant Immunotherapy (DeltEx DRI), is being evaluated as a first-line treatment for newly diagnosed glioblastoma multiforme (GBM). The study involved 23 patients and showed promising progression-free survival (PFS) rates beyond the median expected with standard treatment. There were no dose-limiting toxicities, although some patients experienced adverse events like decreased white blood cell count and fatigue. The presentation will take place on June 1, 2024.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced it will present updated interim results from their Phase 1 trial of INB-100 at the upcoming European Hematology Association (EHA) 2024 Congress in Madrid, June 13-16. INB-100 is a gamma-delta T cell therapy aimed at increasing survival and reducing cancer recurrence in leukemia patients post-haploidentical stem cell transplantation, without severe graft-versus-host disease. The presentation will be held on June 14, 2024, at 10:00 a.m. CEST by Dr. Joseph P. McGuirk. Abstracts are accessible on the EHA website, and the poster will be available on IN8bio's site following the session.
IN8bio presented details about its robust and reproducible gamma-delta T cell therapy manufacturing platform at ASGCT 2024. The data demonstrate significant advancements in the characterization of gamma-delta T cell-based therapies, showing increased potency, effector functions, and trafficking capabilities. The study evaluated T cell products from healthy donors and GBM patients, revealing consistent profiles and gene expression changes throughout the manufacturing process.
IN8bio, Inc. (Nasdaq: INAB) reported financial results for Q1 2024, highlighting progress in gamma-delta T cell programs. Key points include preclinical data on nsCAR platform targeting cancer cells, peer-reviewed publication on DeltEx Drug Resistant Immunotherapy for GBM, and dosing first patient in Phase 2 clinical trial. Financially, R&D expenses increased to $4.9 million, G&A expenses were $3.7 million, net loss was $8.6 million, and cash position stood at $13.0 million.
IN8bio, Inc. (Nasdaq: INAB) has dosed the first patient in a Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma multiforme (GBM). INB-400 is an autologous gamma-delta T cell therapy genetically engineered to survive chemotherapy and enhance cancer cell killing. The trial, expected to enroll up to 40 patients, aims to evaluate safety, tolerability, and overall survival rate at 12 months. INB-400 was granted Orphan Drug Designation in 2023 and is designed to work alongside standard-of-care treatments like temozolomide.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
